Technical Analysis for RYTM - Rhythm Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade C 20.6 3.62% 0.72
RYTM closed up 3.62 percent on Friday, August 16, 2019, on 56 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Up
See historical RYTM trend table...

Date Alert Name Type % Chg
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.00%
Crossed Above 20 DMA Bullish 0.00%
Narrow Range Bar Range Contraction 0.00%
NR7 Range Contraction 0.00%
20 DMA Resistance Bearish 3.62%
Calm After Storm Range Contraction 3.62%
Multiple of Ten Bearish Other 3.62%
20 DMA Resistance Bearish 3.00%
Calm After Storm Range Contraction 3.00%
Fell Below 20 DMA Bearish 9.52%

Older signals for RYTM ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Rhythm Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of peptide therapeutics for the treatment of rare genetic deficiencies that result in life-threatening metabolic disorders. The Company’s lead peptide product candidate is setmelanotide, a potent, first-in-class melanocortin-4 receptor, or MC4R, agonist for the treatment of rare genetic disorders of obesity. Setmelanotide serves as replacement therapy for the treatment of melanocortin-4, or MC4, pathway deficiencies. MC4 pathway deficiencies result in the disruption of satiety signals and energy homeostasis in the body, which, in turn, leads to intense feelings of hunger and to obesity. The Company also focused on obesity related to six single gene-related, or monogenic, MC4 pathway deficiencies pro-opiomelanocortin, or POMC, leptin receptor, or LepR, Bardet-Biedl syndrome, Alstrom syndrome, POMC heterozygous, and POMC epigenetic disorders.
Biopharmaceutical Medical Specialties Organ Systems Obesity Peptide Hormones Peptides Metabolic Disorders
Is RYTM a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 2 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 34.63
52 Week Low 18.0
Average Volume 269,479
200-Day Moving Average 26.0837
50-Day Moving Average 21.204
20-Day Moving Average 20.047
10-Day Moving Average 20.205
Average True Range 1.3131
ADX 19.0
+DI 24.7628
-DI 24.5996
Chandelier Exit (Long, 3 ATRs ) 20.5607
Chandelier Exit (Short, 3 ATRs ) 21.9393
Upper Bollinger Band 21.928
Lower Bollinger Band 18.166
Percent B (%b) 0.65
BandWidth 18.7659
MACD Line -0.3057
MACD Signal Line -0.4465
MACD Histogram 0.1408
Fundamentals Value
Market Cap 537.13 Million
Num Shares 26.1 Million
EPS -3.13
Price-to-Earnings (P/E) Ratio -6.58
Price-to-Sales 0.00
Price-to-Book 0.00
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 21.55
Resistance 3 (R3) 21.46 21.05 21.39
Resistance 2 (R2) 21.05 20.81 21.10 21.33
Resistance 1 (R1) 20.83 20.66 20.94 20.92 21.28
Pivot Point 20.42 20.42 20.48 20.47 20.42
Support 1 (S1) 20.20 20.18 20.31 20.29 19.92
Support 2 (S2) 19.79 20.03 19.84 19.87
Support 3 (S3) 19.57 19.79 19.81
Support 4 (S4) 19.66